Repro Med Systems Stock Performance
| KRMD Stock | USD 3.98 0.06 1.49% |
On a scale of 0 to 100, Repro Med holds a performance score of 18. The company holds a Beta of -0.0495, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Repro Med are expected to decrease at a much lower rate. During the bear market, Repro Med is likely to outperform the market. Please check Repro Med's treynor ratio, kurtosis, period momentum indicator, as well as the relationship between the downside variance and day median price , to make a quick decision on whether Repro Med's historical price patterns will revert.
Risk-Adjusted Performance
18 of 100
Weak | Strong |
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Repro Med Systems are ranked lower than 18 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak primary indicators, Repro Med exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (1.36) | Five Day Return 12.75 | Year To Date Return 67.23 | Ten Year Return 933.77 | All Time Return 3.5 K |
1 | Acquisition by Linda Tharby of 19681 shares of Repro Med at 2.09 subject to Rule 16b-3 | 09/20/2024 |
2 | Acquisition by Manko Joseph M. Jr. of 5454 shares of Repro Med subject to Rule 16b-3 | 09/30/2024 |
3 | Acquisition by Cascella Robert of 5454 shares of Repro Med at 2.75 subject to Rule 16b-3 | 10/01/2024 |
4 | Further weakness as KORU Medical Systems drops 10 percent this week, taking five-year losses to 38 | 10/09/2024 |
5 | LivaNova Tops Q3 Earnings and Revenue Estimates | 10/30/2024 |
6 | KORU Medical Systems Presents Data at Partnership Opportunities in Drug Delivery Conference Demonstrating Nursing Preference for Use of KORU FreedomEdge Infusio... | 10/31/2024 |
7 | Disposition of 721781 shares by Manko Joseph M. Jr. of Repro Med subject to Rule 16b-3 | 11/08/2024 |
8 | KORU Medical Systems, Inc. Announces 2024 Q3 Financial Results, Third Consecutive Quarter of Double-Digit Growth Raises Full Year 2024 Guidance | 11/13/2024 |
9 | Koru Medical Systems stock target increased, holds buy on strong quarter | 11/14/2024 |
10 | KORU Medical Systems, Inc. Q3 2024 Earnings Call Transcript | 11/15/2024 |
11 | KRMD stock touches 52-week high at 3.41 amid robust growth - Investing.com Australia | 11/21/2024 |
12 | KORU Medical Systems to Participate in Piper Sandlers 36th Annual Healthcare Conference | 11/25/2024 |
| Begin Period Cash Flow | 17.4 M | |
| Free Cash Flow | -5.7 M |
Repro |
Repro Med Relative Risk vs. Return Landscape
If you would invest 244.00 in Repro Med Systems on September 2, 2024 and sell it today you would earn a total of 154.00 from holding Repro Med Systems or generate 63.11% return on investment over 90 days. Repro Med Systems is currently generating 0.8285% in daily expected returns and assumes 3.5538% risk (volatility on return distribution) over the 90 days horizon. In different words, 31% of stocks are less volatile than Repro, and 84% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Repro Med Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Repro Med's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Repro Med Systems, and traders can use it to determine the average amount a Repro Med's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2331
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | KRMD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.55 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.83 actual daily | 16 84% of assets have higher returns |
Risk-Adjusted Return
| 0.23 actual daily | 18 82% of assets perform better |
Based on monthly moving average Repro Med is performing at about 18% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Repro Med by adding it to a well-diversified portfolio.
Repro Med Fundamentals Growth
Repro Stock prices reflect investors' perceptions of the future prospects and financial health of Repro Med, and Repro Med fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Repro Stock performance.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.14) % | ||||
| Current Valuation | 177.87 M | ||||
| Shares Outstanding | 45.84 M | ||||
| Price To Earning | 11.56 X | ||||
| Price To Book | 10.29 X | ||||
| Price To Sales | 6.00 X | ||||
| Revenue | 28.52 M | ||||
| Gross Profit | 15.37 M | ||||
| EBITDA | (9.4 M) | ||||
| Net Income | (13.74 M) | ||||
| Cash And Equivalents | 18.27 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 4.45 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 5.40 X | ||||
| Book Value Per Share | 0.45 X | ||||
| Cash Flow From Operations | (4.89 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 184.95 M | ||||
| Total Asset | 28.46 M | ||||
| Retained Earnings | (23.31 M) | ||||
| Working Capital | 15.8 M | ||||
| Current Asset | 2.54 M | ||||
| Current Liabilities | 516.46 K | ||||
About Repro Med Performance
By analyzing Repro Med's fundamental ratios, stakeholders can gain valuable insights into Repro Med's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Repro Med has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Repro Med has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 107.60 | 178.68 | |
| Return On Tangible Assets | (0.50) | (0.47) | |
| Return On Capital Employed | (0.43) | (0.41) | |
| Return On Assets | (0.48) | (0.46) | |
| Return On Equity | (0.68) | (0.64) |
Things to note about Repro Med Systems performance evaluation
Checking the ongoing alerts about Repro Med for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Repro Med Systems help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Repro Med Systems appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 28.52 M. Net Loss for the year was (13.74 M) with profit before overhead, payroll, taxes, and interest of 15.37 M. | |
| Repro Med Systems currently holds about 18.27 M in cash with (4.89 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.41. | |
| Latest headline from businesswire.com: KORU Medical Systems to Participate in Piper Sandlers 36th Annual Healthcare Conference |
- Analyzing Repro Med's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Repro Med's stock is overvalued or undervalued compared to its peers.
- Examining Repro Med's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Repro Med's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Repro Med's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Repro Med's stock. These opinions can provide insight into Repro Med's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Repro Stock analysis
When running Repro Med's price analysis, check to measure Repro Med's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Repro Med is operating at the current time. Most of Repro Med's value examination focuses on studying past and present price action to predict the probability of Repro Med's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Repro Med's price. Additionally, you may evaluate how the addition of Repro Med to your portfolios can decrease your overall portfolio volatility.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |